{
  "id": "wernicke-korsakoff-syndrome",
  "title": "Wernicke-Korsakoff Syndrome",
  "version": "1.1",
  "icd10": [
    "** F10.96 (Alcohol use",
    "unspecified with alcohol-induced persisting amnestic disorder)",
    "F10.26 (Alcohol dependence with alcohol-induced persisting amnestic disorder)",
    "E51.2 (Wernicke encephalopathy)"
  ],
  "scope": "** Evaluation and management of Wernicke-Korsakoff syndrome including the chronic Korsakoff amnestic component, differentiation from isolated Wernicke encephalopathy, long-term cognitive rehabilitation, and nutritional management. Covers transition from acute Wernicke encephalopathy to chronic Korsakoff syndrome, cognitive assessment, pharmacologic and non-pharmacologic interventions for memory impairment, behavioral management, and disposition planning. Applies to ED (acute decompensation/re-presentation), HOSP (initial stabilization and workup), OPD (long-term management and rehabilitation), and ICU (severe cases with hemodynamic or respiratory compromise). For acute Wernicke encephalopathy management, see the dedicated Wernicke Encephalopathy plan.",
  "notes": [],
  "sections": {
    "Laboratory Workup": {
      "Core Labs": [
        {
          "item": "BMP",
          "rationale": "Electrolyte abnormalities common in malnutrition and alcohol use; renal function for medication dosing",
          "target": "Normal electrolytes",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Magnesium",
          "rationale": "Required cofactor for thiamine-dependent enzymes; frequently depleted in alcohol use disorder",
          "target": ">2.0 mg/dL",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Phosphorus",
          "rationale": "Refeeding syndrome risk; depleted in malnutrition",
          "target": ">2.5 mg/dL",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "CBC with differential",
          "rationale": "Macrocytic anemia (B12/folate/alcohol); infection screening; thrombocytopenia in liver disease",
          "target": "Document; MCV often elevated",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "LFTs including albumin",
          "rationale": "Hepatic dysfunction; nutritional status; alcohol-related liver disease",
          "target": "Document severity",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Ammonia",
          "rationale": "Hepatic encephalopathy may coexist or mimic Korsakoff; critical to differentiate",
          "target": "Normal; if elevated, treat hepatic encephalopathy",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Fingerstick glucose",
          "rationale": "Hypoglycemia from malnutrition/liver disease; give thiamine before dextrose",
          "target": "Normal; treat after thiamine",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Blood alcohol level",
          "rationale": "Document active use; assess withdrawal risk; guide management",
          "target": "Document",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "-"
        },
        {
          "item": "Thiamine level (whole blood)",
          "rationale": "Baseline thiamine status; low levels support diagnosis but do not delay treatment",
          "target": "Low supports diagnosis; treat empirically regardless",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        }
      ],
      "Extended Workup": [
        {
          "item": "Vitamin B12 and folate",
          "rationale": "Frequently co-deficient in alcohol use disorder; contributes to macrocytic anemia and neuropathy",
          "target": "Normal; supplement if low",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "TSH",
          "rationale": "Hypothyroidism may contribute to cognitive impairment and must be excluded",
          "target": "Normal",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "RPR/VDRL",
          "rationale": "Neurosyphilis can cause cognitive decline and amnesia; must exclude in at-risk patients",
          "target": "Non-reactive",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "HIV testing",
          "rationale": "HIV-associated neurocognitive disorder may mimic or coexist; at-risk population overlap",
          "target": "Non-reactive",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Coagulation studies (PT/INR)",
          "rationale": "Liver synthetic function; coagulopathy risk in alcohol-related liver disease",
          "target": "Normal",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "ROUTINE"
        },
        {
          "item": "Urine drug screen",
          "rationale": "Identify concurrent substance use affecting cognition and behavior",
          "target": "Document; manage polysubstance use",
          "ED": "STAT",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "-"
        },
        {
          "item": "HbA1c",
          "rationale": "Chronic glycemic control; diabetes contributes to cognitive impairment and neuropathy",
          "target": "<7%",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "25-hydroxyvitamin D",
          "rationale": "Deficiency common in alcohol use and malnutrition; contributes to bone health and cognitive function",
          "target": ">30 ng/mL",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Specialized Labs (If Diagnosis Uncertain)": [
        {
          "item": "RBC transketolase activity",
          "rationale": "Functional thiamine status; most specific marker of thiamine deficiency",
          "target": "Low activity confirms deficiency",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "Thiamine pyrophosphate (TPP) effect",
          "rationale": ">25% increase after TPP addition indicates deficiency; more sensitive than total thiamine",
          "target": "<15% normal; >25% deficient",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "Methylmalonic acid and homocysteine",
          "rationale": "Differentiates B12 deficiency from folate deficiency; relevant to cognitive impairment",
          "target": "Normal MMA excludes B12 deficiency",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Heavy metal screen (lead, mercury)",
          "rationale": "Chronic exposure may cause cognitive impairment; consider in occupational/environmental risk",
          "target": "Normal",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "Ceruloplasmin and serum copper",
          "rationale": "Wilson disease exclusion in younger patients with cognitive-psychiatric presentation",
          "target": "Normal",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "-"
        }
      ]
    },
    "Imaging & Studies": {
      "Essential Neuroimaging": [
        {
          "item": "MRI brain with FLAIR/DWI",
          "timing": "Within 24-48 hours of presentation; or at initial outpatient evaluation",
          "target": "Bilateral symmetric T2/FLAIR hyperintensity in mammillary bodies, medial thalami, periaqueductal gray; mammillary body atrophy in chronic KS; cortical atrophy; cerebellar vermis atrophy",
          "contraindications": "Pacemaker; metal implants; severe claustrophobia",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "ROUTINE",
          "ICU": "URGENT"
        },
        {
          "item": "CT head without contrast",
          "timing": "Immediate if altered mental status; exclude hemorrhage, mass, hydrocephalus",
          "target": "No acute hemorrhage or mass; may show cerebral atrophy; often normal in WKS",
          "contraindications": "None",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        }
      ],
      "Extended Imaging": [
        {
          "item": "MRI brain volumetric analysis",
          "timing": "Outpatient follow-up; quantify atrophy progression",
          "target": "Mammillary body volume loss; thalamic atrophy; frontal cortical thinning; hippocampal atrophy",
          "contraindications": "Same as MRI",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "CT head without contrast (if MRI unavailable)",
          "timing": "Acute setting when MRI not feasible",
          "target": "Cerebral atrophy; thalamic hypodensity (rare); exclude other pathology",
          "contraindications": "Pregnancy (relative)",
          "ED": "STAT",
          "HOSP": "URGENT",
          "OPD": "-",
          "ICU": "STAT"
        }
      ],
      "Additional Studies": [
        {
          "item": "EEG",
          "timing": "If seizure suspected or unexplained encephalopathy",
          "target": "Diffuse slowing (non-specific); rule out non-convulsive status epilepticus",
          "contraindications": "None",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "ROUTINE"
        },
        {
          "item": "FDG-PET brain",
          "timing": "Consider if atypical dementia pattern; research/specialist evaluation",
          "target": "Bilateral thalamic and frontal hypometabolism in KS",
          "contraindications": "Pregnancy; uncontrolled glucose",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "Neuropsychological testing (formal)",
          "timing": "After acute phase resolves; outpatient baseline and serial assessment",
          "target": "Severe anterograde amnesia; impaired executive function; relative preservation of procedural memory and IQ",
          "contraindications": "Requires patient cooperation; unreliable if acutely confused",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ]
    },
    "Treatment": {
      "Acute Thiamine Replacement (If Presenting with Active WE Component)": [
        {
          "item": "Thiamine IV (high-dose)",
          "route": "IV",
          "indication": "Acute Wernicke encephalopathy treatment or acute decompensation of WKS",
          "dosing": {
            "doseOptions": [
              {
                "text": "500 mg",
                "orderSentence": "Thiamine IV (high-dose) 500 mg IV"
              }
            ],
            "route": "IV",
            "instructions": "500 mg IV TID in 100 mL NS over 30 min x 3-5 days; then 250 mg IV daily x 3-5 days; then transition to oral",
            "orderSentence": "Thiamine IV (high-dose) 500 mg IV"
          },
          "contraindications": "Rare anaphylaxis (administer slowly; have epinephrine available)",
          "monitoring": "Anaphylaxis monitoring during infusion; clinical response (mental status, oculomotor function, gait)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Thiamine IV (prophylactic - at-risk re-presentation)",
          "route": "IV",
          "indication": "Prophylaxis in known WKS patients presenting with acute illness, poor oral intake, or suspected relapse",
          "dosing": {
            "doseOptions": [
              {
                "text": "200-500 mg",
                "orderSentence": "Thiamine IV (prophylactic - at-risk re-presentation) 200-500 mg IV"
              }
            ],
            "route": "IV",
            "instructions": "200-500 mg IV TID x 3 days; reassess and transition to oral when tolerating",
            "orderSentence": "Thiamine IV (prophylactic - at-risk re-presentation) 200-500 mg IV"
          },
          "contraindications": "Rare anaphylaxis",
          "monitoring": "Anaphylaxis monitoring; clinical response",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Magnesium sulfate IV",
          "route": "IV",
          "indication": "Magnesium replacement as essential cofactor for thiamine-dependent enzymes",
          "dosing": {
            "doseOptions": [
              {
                "text": "1-2 g",
                "orderSentence": "Magnesium sulfate IV 1-2 g IV"
              }
            ],
            "route": "IV",
            "instructions": "1-2 g IV over 1-2 hours; repeat as needed to maintain Mg >2.0 mg/dL",
            "orderSentence": "Magnesium sulfate IV 1-2 g IV"
          },
          "contraindications": "Renal failure (dose adjust); heart block; myasthenia gravis",
          "monitoring": "Magnesium levels; deep tendon reflexes; renal function",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        }
      ],
      "Chronic Thiamine and Nutritional Supplementation": [
        {
          "item": "Thiamine oral (maintenance)",
          "route": "PO",
          "indication": "Long-term thiamine supplementation to prevent further neuronal damage and support residual thiamine-dependent function",
          "dosing": {
            "doseOptions": [
              {
                "text": "100 mg",
                "orderSentence": "Thiamine oral (maintenance) 100 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 100 mg TID for 3-6 months after acute treatment; may reduce to 100 mg daily for indefinite maintenance if ongoing risk factors",
            "orderSentence": "Thiamine oral (maintenance) 100 mg PO"
          },
          "contraindications": "None significant",
          "monitoring": "Compliance assessment at each visit; thiamine levels if concern for non-adherence",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Thiamine IM",
          "route": "IM",
          "indication": "Alternative when oral absorption unreliable (active alcohol use, GI malabsorption, non-compliance with oral)",
          "dosing": {
            "doseOptions": [
              {
                "text": "250 mg",
                "orderSentence": "Thiamine IM 250 mg IM"
              }
            ],
            "route": "IM",
            "instructions": "250 mg IM daily x 5 days then 250 mg IM 3x/week if oral not feasible",
            "orderSentence": "Thiamine IM 250 mg IM"
          },
          "contraindications": "Coagulopathy (relative); anticoagulation",
          "monitoring": "Injection site; clinical response; compliance",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Folate",
          "route": "PO",
          "indication": "Folate deficiency commonly co-occurs in alcohol use disorder; required for DNA synthesis and neuronal health",
          "dosing": {
            "doseOptions": [
              {
                "text": "1 mg",
                "orderSentence": "Folate 1 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "1 mg PO daily; indefinite in patients with ongoing alcohol use or poor nutrition",
            "orderSentence": "Folate 1 mg PO"
          },
          "contraindications": "None",
          "monitoring": "Folate levels annually",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Multivitamin with minerals",
          "route": "PO",
          "indication": "Broad nutritional repletion in chronically malnourished patients",
          "dosing": {
            "doseOptions": [
              {
                "text": "1 tablet",
                "orderSentence": "Multivitamin with minerals 1 tablet PO"
              }
            ],
            "route": "PO",
            "instructions": "1 tablet PO daily; indefinite",
            "orderSentence": "Multivitamin with minerals 1 tablet PO"
          },
          "contraindications": "None",
          "monitoring": "General nutritional assessment",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Vitamin B12 (cyanocobalamin)",
          "route": "PO/IM",
          "indication": "B12 deficiency frequently co-occurs; contributes to peripheral neuropathy and cognitive impairment",
          "dosing": {
            "doseOptions": [
              {
                "text": "1000 mcg",
                "orderSentence": "Vitamin B12 (cyanocobalamin) 1000 mcg PO"
              }
            ],
            "route": "PO",
            "instructions": "1000 mcg PO daily if B12 low; or 1000 mcg IM monthly if malabsorption",
            "orderSentence": "Vitamin B12 (cyanocobalamin) 1000 mcg PO"
          },
          "contraindications": "None",
          "monitoring": "B12 levels; MMA if uncertain",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Vitamin D3 (cholecalciferol)",
          "route": "PO",
          "indication": "Deficiency common in alcohol use and malnutrition; bone health and potential cognitive benefit",
          "dosing": {
            "doseOptions": [
              {
                "text": "2000 IU",
                "orderSentence": "Vitamin D3 (cholecalciferol) 2000 IU PO"
              }
            ],
            "route": "PO",
            "instructions": "2000-5000 IU PO daily based on level; recheck in 3 months",
            "orderSentence": "Vitamin D3 (cholecalciferol) 2000 IU PO"
          },
          "contraindications": "Hypercalcemia; sarcoidosis",
          "monitoring": "25-OH vitamin D level; calcium",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Cognitive and Behavioral Pharmacotherapy": [
        {
          "item": "Donepezil",
          "route": "PO",
          "indication": "Cholinergic augmentation for memory impairment in Korsakoff syndrome; limited but suggestive evidence of benefit in alcohol-related cognitive impairment",
          "dosing": {
            "doseOptions": [
              {
                "text": "5 mg",
                "orderSentence": "Donepezil 5 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 5 mg PO daily x 4-6 weeks; increase to 10 mg daily if tolerated; assess cognitive response at 3 months",
            "orderSentence": "Donepezil 5 mg PO"
          },
          "contraindications": "Sick sinus syndrome; AV block; active GI bleeding; severe COPD/asthma",
          "monitoring": "Heart rate (bradycardia); GI symptoms (nausea, diarrhea); weight; MMSE or MoCA at baseline and q3-6 months",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Memantine",
          "route": "PO",
          "indication": "NMDA receptor antagonist for moderate-severe cognitive impairment; may reduce excitotoxicity in alcohol-related brain damage",
          "dosing": {
            "doseOptions": [
              {
                "text": "5 mg",
                "orderSentence": "Memantine 5 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 5 mg PO daily; increase by 5 mg/week; target 10 mg BID; max 20 mg/day",
            "orderSentence": "Memantine 5 mg PO"
          },
          "contraindications": "Severe renal impairment (CrCl <30); concurrent use of other NMDA antagonists",
          "monitoring": "Renal function; confusion; dizziness; cognitive assessment q3-6 months",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Sertraline",
          "route": "PO",
          "indication": "Depression and apathy commonly comorbid in Korsakoff syndrome; SSRI with evidence in alcohol-related depression",
          "dosing": {
            "doseOptions": [
              {
                "text": "25 mg",
                "orderSentence": "Sertraline 25 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 25 mg PO daily; increase by 25-50 mg q1-2 weeks; target 50-150 mg daily; max 200 mg/day",
            "orderSentence": "Sertraline 25 mg PO"
          },
          "contraindications": "Concurrent MAOIs; uncontrolled narrow-angle glaucoma",
          "monitoring": "Suicidality in first weeks; sodium (SIADH risk); GI bleeding risk with concurrent NSAIDs; mood and function assessment",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Mirtazapine",
          "route": "PO",
          "indication": "Depression with insomnia, poor appetite, and weight loss in Korsakoff syndrome; promotes appetite and sleep",
          "dosing": {
            "doseOptions": [
              {
                "text": "7.5 mg",
                "orderSentence": "Mirtazapine 7.5 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 7.5-15 mg PO qHS; increase by 15 mg q1-2 weeks; max 45 mg qHS; more sedating at lower doses",
            "orderSentence": "Mirtazapine 7.5 mg PO"
          },
          "contraindications": "Concurrent MAOIs; severe hepatic impairment",
          "monitoring": "Weight; metabolic panel; sedation; mood assessment",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Trazodone",
          "route": "PO",
          "indication": "Insomnia and sleep-wake cycle disruption common in Korsakoff syndrome; avoids benzodiazepine dependence risk",
          "dosing": {
            "doseOptions": [
              {
                "text": "25 mg",
                "orderSentence": "Trazodone 25 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 25-50 mg PO qHS; titrate by 25-50 mg q3-5 days; max 200 mg qHS for insomnia",
            "orderSentence": "Trazodone 25 mg PO"
          },
          "contraindications": "Priapism risk (rare); concurrent MAOIs; severe hepatic impairment",
          "monitoring": "Orthostatic hypotension; excessive sedation; priapism (counsel patient)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Quetiapine (low-dose)",
          "route": "PO",
          "indication": "Agitation, psychosis, or severe behavioral disturbance in Korsakoff syndrome not responsive to non-pharmacologic measures",
          "dosing": {
            "doseOptions": [
              {
                "text": "12.5 mg",
                "orderSentence": "Quetiapine (low-dose) 12.5 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 12.5-25 mg PO BID; titrate slowly by 25 mg q3-5 days; max 200 mg/day; use lowest effective dose",
            "orderSentence": "Quetiapine (low-dose) 12.5 mg PO"
          },
          "contraindications": "Parkinsonism; QTc prolongation; dementia-related psychosis (FDA black box); uncontrolled diabetes",
          "monitoring": "Metabolic panel; HbA1c; QTc; extrapyramidal symptoms; falls; sedation; annual movement disorder screening",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Haloperidol",
          "route": "IV/IM/PO",
          "indication": "Acute severe agitation or psychosis in hospitalized WKS patients when immediate control needed",
          "dosing": {
            "doseOptions": [
              {
                "text": "0.5 mg",
                "orderSentence": "Haloperidol 0.5 mg IV/IM"
              }
            ],
            "route": "IV/IM",
            "instructions": "0.5-2 mg IV/IM q4-6h PRN agitation; max 10 mg/day; switch to oral/atypical ASAP",
            "orderSentence": "Haloperidol 0.5 mg IV/IM"
          },
          "contraindications": "QTc prolongation; Parkinsonism; dementia-related psychosis (FDA black box); neuroleptic malignant syndrome",
          "monitoring": "QTc monitoring; extrapyramidal symptoms; sedation level; vital signs",
          "ED": "URGENT",
          "HOSP": "URGENT",
          "OPD": "-",
          "ICU": "URGENT"
        }
      ],
      "Alcohol Use Disorder Treatment": [
        {
          "item": "Naltrexone",
          "route": "PO",
          "indication": "Reduction of alcohol craving and relapse prevention in patients with Korsakoff syndrome and ongoing alcohol use disorder",
          "dosing": {
            "doseOptions": [
              {
                "text": "25 mg",
                "orderSentence": "Naltrexone 25 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 25 mg PO daily x 3 days; then 50 mg PO daily; assess tolerability and compliance",
            "orderSentence": "Naltrexone 25 mg PO"
          },
          "contraindications": "Acute hepatitis or hepatic failure (LFTs >3x ULN); concurrent opioid use; opioid dependence",
          "monitoring": "LFTs at baseline and monthly x 3 months then q3 months; compliance; craving assessment",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Naltrexone IM (Vivitrol)",
          "route": "IM",
          "indication": "Extended-release formulation for alcohol relapse prevention when oral compliance is poor (common in Korsakoff syndrome due to memory impairment)",
          "dosing": {
            "doseOptions": [
              {
                "text": "380 mg",
                "orderSentence": "Naltrexone IM (Vivitrol) 380 mg IM"
              }
            ],
            "route": "IM",
            "instructions": "380 mg IM gluteal injection every 4 weeks; requires opioid-free x 7-10 days",
            "orderSentence": "Naltrexone IM (Vivitrol) 380 mg IM"
          },
          "contraindications": "Acute hepatitis; hepatic failure; opioid use/dependence",
          "monitoring": "LFTs at baseline and periodically; injection site reactions; compliance with monthly visits",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Acamprosate",
          "route": "PO",
          "indication": "Reduces alcohol craving by modulating glutamate/GABA balance; safe in hepatic impairment (renally cleared)",
          "dosing": {
            "doseOptions": [
              {
                "text": "666 mg",
                "orderSentence": "Acamprosate 666 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "666 mg PO TID; reduce to 333 mg TID if CrCl 30-50; contraindicated if CrCl <30",
            "orderSentence": "Acamprosate 666 mg PO"
          },
          "contraindications": "Severe renal impairment (CrCl <30)",
          "monitoring": "Renal function; diarrhea (common); compliance; craving assessment",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Gabapentin (off-label for alcohol use disorder)",
          "route": "PO",
          "indication": "Adjunctive treatment for alcohol craving and insomnia; reduces alcohol consumption; also treats concurrent neuropathic pain",
          "dosing": {
            "doseOptions": [
              {
                "text": "300 mg",
                "orderSentence": "Gabapentin (off-label for alcohol use disorder) 300 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 300 mg PO qHS; titrate by 300 mg q3-5 days; target 600-1800 mg/day divided TID; max 1800 mg/day for AUD",
            "orderSentence": "Gabapentin (off-label for alcohol use disorder) 300 mg PO"
          },
          "contraindications": "Renal impairment (dose adjust); respiratory depression risk with opioids",
          "monitoring": "Sedation; dizziness; renal function; edema; suicidal ideation",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Alcohol Withdrawal Management (If Presenting with Active Withdrawal)": [
        {
          "item": "Lorazepam (symptom-triggered)",
          "route": "IV/PO",
          "indication": "Alcohol withdrawal prevention and treatment in WKS patients; preferred in hepatic impairment due to no active metabolites",
          "dosing": {
            "doseOptions": [
              {
                "text": "1-2 mg",
                "orderSentence": "Lorazepam (symptom-triggered) 1-2 mg IV"
              }
            ],
            "route": "IV",
            "instructions": "1-4 mg IV q15-30 min PRN based on CIWA score (CIWA >10); or 1-2 mg PO q4-6h PRN; max guided by clinical response",
            "orderSentence": "Lorazepam (symptom-triggered) 1-2 mg IV"
          },
          "contraindications": "Severe respiratory depression without ventilator support; acute narrow-angle glaucoma",
          "monitoring": "CIWA score q4-8h; respiratory status; sedation level; hemodynamics",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Chlordiazepoxide (scheduled taper)",
          "route": "PO",
          "indication": "Alcohol withdrawal prophylaxis when patient is hemodynamically stable and tolerating oral medications",
          "dosing": {
            "doseOptions": [
              {
                "text": "25 mg",
                "orderSentence": "Chlordiazepoxide (scheduled taper) 25 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "25-50 mg PO QID day 1-2; taper by 25% daily over 4-7 days; hold for oversedation",
            "orderSentence": "Chlordiazepoxide (scheduled taper) 25 mg PO"
          },
          "contraindications": "Severe hepatic impairment (use lorazepam instead); respiratory depression",
          "monitoring": "CIWA score; sedation level; hepatic function; respiratory status",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "-"
        }
      ]
    },
    "Other Recommendations": {
      "Referrals & Consults": [
        {
          "item": "Neurology consult for diagnosis confirmation, differentiation from other dementias, and long-term cognitive management planning",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "Neuropsychology referral for formal cognitive assessment including memory, executive function, and functional capacity evaluation",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Addiction medicine or psychiatry consult for alcohol use disorder treatment, relapse prevention, and dual-diagnosis management",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Physical therapy for gait training, balance rehabilitation, and fall prevention given persistent cerebellar ataxia",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Occupational therapy for ADL assessment, compensatory strategy training, and memory aid implementation for daily functioning",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Speech-language pathology for cognitive-linguistic assessment, memory strategy training, and swallowing evaluation if dysphagia present",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Social work for discharge planning, residential placement assessment, guardianship evaluation, and community resource coordination",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Nutrition/dietitian consult for nutritional rehabilitation, meal planning, and ongoing supplementation guidance",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "Cognitive rehabilitation specialist for errorless learning protocols, spaced retrieval training, and compensatory memory strategy development",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Palliative care consult for goals of care discussion in patients with severe irreversible Korsakoff syndrome and significant functional impairment",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Patient and Family Instructions": [
        {
          "item": "Wernicke-Korsakoff syndrome causes brain damage from thiamine (vitamin B1) deficiency, usually related to alcohol use; the memory problems may be permanent but can stabilize with treatment",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Take thiamine supplements exactly as prescribed every day; missing doses can worsen brain damage",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Complete abstinence from alcohol is essential to prevent further brain injury and allow maximum recovery",
          "ED": "ROUTINE",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Memory problems may make it difficult to remember medications; use pill organizers, phone alarms, and caregiver reminders",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Return to the emergency department immediately if confusion worsens, new vision problems develop, or walking becomes significantly more unsteady (may indicate acute decompensation)",
          "ED": "ROUTINE",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Do not drive or operate heavy machinery until formally evaluated by neurology and neuropsychology due to cognitive impairment and impaired judgment",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Eat regular balanced meals including foods high in thiamine (whole grains, legumes, pork, nuts); malnutrition worsens symptoms",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "The confabulation (making up stories without realizing it) is part of the illness and is not intentional lying; families should gently redirect rather than confront",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "SAMHSA National Helpline 1-800-662-4357 for free alcohol treatment referrals and information",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Caregivers should attend follow-up appointments to provide collateral history and receive education on disease management",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Lifestyle and Rehabilitation": [
        {
          "item": "Absolute alcohol abstinence to prevent further thiamine depletion and progressive neuronal damage",
          "ED": "ROUTINE",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Structured daily routine with consistent mealtimes, medication times, and activities to support residual memory function through procedural learning",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Environmental modifications including written schedules posted in visible locations, labeled rooms and drawers, and simplified living space to reduce cognitive demand",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Fall prevention measures including non-skid footwear, removal of home hazards, grab bars in bathroom, and assistive device use given persistent gait ataxia",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Supervised medication administration by caregiver or structured program given inability to reliably self-administer due to anterograde amnesia",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Cognitive stimulation through structured activities (puzzles, music therapy, reminiscence therapy) to promote engagement and maintain existing cognitive function",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Nutritional counseling with high-thiamine diet including whole grains, enriched cereals, legumes, lean pork, nuts, and seeds",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Supervised community living or structured residential placement if unable to live independently due to cognitive impairment and safety concerns",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Caregiver respite resources and support groups to prevent caregiver burnout given high care burden of chronic amnestic syndrome",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Regular exercise program adapted to functional level to improve cardiovascular health, mood, and maintain mobility",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ]
    }
  },
  "differential": [
    {
      "diagnosis": "Alzheimer disease",
      "features": "Gradual onset; temporal lobe atrophy on MRI; amyloid/tau biomarkers positive; no alcohol history required; hippocampal atrophy predominates",
      "tests": "MRI volumetrics; CSF amyloid-beta/tau; PET amyloid imaging"
    },
    {
      "diagnosis": "Hepatic encephalopathy",
      "features": "Asterixis; elevated ammonia; liver disease; fluctuating course; reversible with lactulose/rifaximin",
      "tests": "Ammonia level; LFTs; liver imaging; clinical response to treatment"
    },
    {
      "diagnosis": "Vascular dementia",
      "features": "Stepwise decline; focal neurological signs; vascular risk factors; white matter disease on imaging",
      "tests": "MRI (lacunar infarcts, periventricular white matter changes); vascular risk profile"
    },
    {
      "diagnosis": "Alcohol-related dementia (non-Korsakoff)",
      "features": "Global cognitive decline without disproportionate amnesia; cortical atrophy; no confabulation",
      "tests": "Neuropsychological testing shows global pattern vs. disproportionate amnesia in KS; MRI pattern differs"
    },
    {
      "diagnosis": "Herpes simplex encephalitis (chronic sequelae)",
      "features": "History of acute febrile encephalitis; temporal lobe necrosis on MRI; anterograde amnesia can be similar",
      "tests": "MRI (temporal lobe signal changes); CSF HSV PCR history; temporal lobe atrophy"
    },
    {
      "diagnosis": "Transient global amnesia",
      "features": "Sudden onset; resolves within 24 hours; no confusion or confabulation after resolution; single episode",
      "tests": "Clinical course (self-resolving); DWI may show hippocampal restriction"
    },
    {
      "diagnosis": "Normal pressure hydrocephalus",
      "features": "Triad of gait apraxia, urinary incontinence, and dementia; ventriculomegaly out of proportion to atrophy",
      "tests": "MRI (enlarged ventricles, tight sulci); large-volume LP trial with gait assessment pre/post"
    },
    {
      "diagnosis": "Limbic encephalitis (autoimmune)",
      "features": "Subacute onset; seizures; psychiatric symptoms; antibody-mediated; may respond to immunotherapy",
      "tests": "Autoimmune encephalitis antibody panel (LGI1, CASPR2, NMDAR); CSF analysis; MRI medial temporal signal"
    },
    {
      "diagnosis": "Chronic traumatic encephalopathy",
      "features": "Progressive cognitive/behavioral decline; history of repetitive head trauma; no specific biomarker",
      "tests": "Clinical history of head trauma; diagnosis of exclusion; confirmed only on autopsy"
    },
    {
      "diagnosis": "Frontotemporal dementia (behavioral variant)",
      "features": "Personality change and behavioral disinhibition predominate; executive dysfunction; frontal atrophy",
      "tests": "Neuropsychological profile; MRI (frontal/temporal atrophy pattern); FDG-PET"
    },
    {
      "diagnosis": "Medication-induced cognitive impairment",
      "features": "Temporal correlation with medication changes; reversible with discontinuation",
      "tests": "Medication reconciliation; improvement after dose reduction or discontinuation"
    }
  ],
  "evidence": [
    {
      "recommendation": "High-dose IV thiamine (500 mg TID) for WE treatment and prevention of Korsakoff syndrome",
      "evidenceLevel": "Class II, Level B",
      "source": "[Galvin R et al. Cochrane Database Syst Rev 2010](https://pubmed.ncbi.nlm.nih.gov/20614462/); [Thomson AD et al. Alcohol Alcohol 2002](https://pubmed.ncbi.nlm.nih.gov/12414541/)"
    },
    {
      "recommendation": "Korsakoff syndrome develops in approximately 80% of untreated or inadequately treated WE cases",
      "evidenceLevel": "Class II, Level B",
      "source": "[Victor M, Adams RD, Collins GH. The Wernicke-Korsakoff Syndrome and Related Neurologic Disorders Due to Alcoholism and Malnutrition. 1989](https://pubmed.ncbi.nlm.nih.gov/2667707/)"
    },
    {
      "recommendation": "MRI findings (mammillary body atrophy, thalamic signal changes) support WKS diagnosis",
      "evidenceLevel": "Class II, Level B",
      "source": "[Zuccoli G et al. AJNR Am J Neuroradiol 2007](https://pubmed.ncbi.nlm.nih.gov/17893203/); [Sullivan EV, Pfefferbaum A. Neuropsychol Rev 2009](https://pubmed.ncbi.nlm.nih.gov/19184444/)"
    },
    {
      "recommendation": "Errorless learning and spaced retrieval techniques improve functional outcomes in Korsakoff syndrome",
      "evidenceLevel": "Class II, Level B",
      "source": "[Oudman E et al. Neuropsychol Rev 2015](https://pubmed.ncbi.nlm.nih.gov/26412231/)"
    },
    {
      "recommendation": "Cholinesterase inhibitors (donepezil) show limited but suggestive benefit in alcohol-related cognitive impairment",
      "evidenceLevel": "Class III, Level C",
      "source": "[Rustembegovic A et al. Med Arh 2003](https://pubmed.ncbi.nlm.nih.gov/14608170/)"
    },
    {
      "recommendation": "Oral thiamine has limited bioavailability in patients with alcohol use disorder; parenteral route preferred",
      "evidenceLevel": "Class II, Level B",
      "source": "[Thomson AD, Marshall EJ. Alcohol Alcohol 2006](https://pubmed.ncbi.nlm.nih.gov/16855004/)"
    },
    {
      "recommendation": "Magnesium is essential cofactor for thiamine pyrophosphokinase; replacement critical for thiamine efficacy",
      "evidenceLevel": "Class II, Level B",
      "source": "[Traviesa DC. Am J Clin Nutr 1974](https://pubmed.ncbi.nlm.nih.gov/4472911/)"
    },
    {
      "recommendation": "Naltrexone and acamprosate reduce alcohol relapse; critical for preventing WKS progression",
      "evidenceLevel": "Class I, Level A",
      "source": "[Jonas DE et al. JAMA 2014](https://pubmed.ncbi.nlm.nih.gov/24825643/)"
    },
    {
      "recommendation": "Neuropsychological profile of Korsakoff syndrome: disproportionate amnesia with relatively preserved IQ and procedural memory",
      "evidenceLevel": "Class II, Level B",
      "source": "[Kopelman MD et al. Neuropsychol Rev 2009](https://pubmed.ncbi.nlm.nih.gov/19430900/)"
    },
    {
      "recommendation": "EFNS guidelines for diagnosis and management of Wernicke encephalopathy",
      "evidenceLevel": "Class II, Level B",
      "source": "[Galvin R et al. Eur J Neurol 2010](https://pubmed.ncbi.nlm.nih.gov/20236172/)"
    },
    {
      "recommendation": "Recovery from Korsakoff syndrome: approximately 25% show significant improvement with adequate treatment and abstinence",
      "evidenceLevel": "Class II, Level C",
      "source": "[Kopelman MD. J Neurol Neurosurg Psychiatry 1995](https://pubmed.ncbi.nlm.nih.gov/7629519/)"
    }
  ],
  "monitoring": [
    {
      "item": "Mental status (orientation, attention, memory)",
      "frequency": "Every visit; q4-8h inpatient",
      "action": "Investigate new causes of decline; increase thiamine; adjust medications; reassess diagnosis",
      "ED": "STAT",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "STAT"
    },
    {
      "item": "MoCA or MMSE (standardized cognitive screening)",
      "frequency": "Baseline and q3-6 months outpatient",
      "action": "Adjust cognitive pharmacotherapy; increase rehabilitation intensity; reassess living situation",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Formal neuropsychological testing",
      "frequency": "Baseline at 3 months post-acute; then annually",
      "action": "Modify rehabilitation goals; adjust medication; reassess disposition and level of care",
      "ED": "-",
      "HOSP": "-",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Thiamine level (whole blood)",
      "frequency": "Baseline; recheck at 3 months; then annually",
      "action": "Increase oral dose; check compliance; consider IM route if non-adherent or malabsorbing",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Magnesium",
      "frequency": "Daily inpatient until stable; q3-6 months outpatient",
      "action": "Oral or IV supplementation; assess dietary intake",
      "ED": "STAT",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "STAT"
    },
    {
      "item": "LFTs",
      "frequency": "Baseline; q3 months if on hepatotoxic medications; annually otherwise",
      "action": "Adjust medications; hepatology referral if worsening; assess ongoing alcohol use",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Nutritional status (albumin, prealbumin, weight)",
      "frequency": "Monthly inpatient; q3-6 months outpatient",
      "action": "Intensify nutritional support; dietitian re-evaluation; assess for ongoing alcohol use or malabsorption",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "ROUTINE"
    },
    {
      "item": "Gait and balance assessment",
      "frequency": "Every visit; formal PT assessment q3-6 months",
      "action": "Adjust PT program; consider assistive device; fall prevention reassessment",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Medication compliance",
      "frequency": "Every visit",
      "action": "Implement medication management system; caregiver education; consider long-acting formulations; IM thiamine if oral non-adherent",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Alcohol use assessment (AUDIT, PEth level)",
      "frequency": "Every visit; PEth if relapse suspected",
      "action": "Addiction medicine re-referral; intensify behavioral treatment; consider naltrexone IM; reassess safety",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Depression screening (PHQ-9)",
      "frequency": "Baseline and q3-6 months",
      "action": "Initiate or adjust antidepressant; behavioral activation; therapy referral",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Functional independence (FIM or Barthel Index)",
      "frequency": "Baseline; monthly during rehabilitation; q6 months thereafter",
      "action": "Modify rehabilitation plan; reassess level of care; consider more supervised living",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    }
  ],
  "disposition": [
    {
      "disposition": "Admit to hospital",
      "criteria": "Suspected acute Wernicke encephalopathy requiring IV thiamine; new-onset confusion in known WKS patient; severe malnutrition requiring supervised refeeding; active alcohol withdrawal"
    },
    {
      "disposition": "ICU admission",
      "criteria": "Altered mental status with hemodynamic instability; severe alcohol withdrawal (CIWA >20 or seizures); respiratory compromise; refeeding syndrome with electrolyte instability"
    },
    {
      "disposition": "Step-down to floor",
      "criteria": "Hemodynamically stable; CIWA <10 or withdrawal resolved; tolerating oral intake; no ongoing electrolyte instability"
    },
    {
      "disposition": "Discharge to rehabilitation facility",
      "criteria": "Medically stable; persistent cognitive and functional deficits requiring intensive rehabilitation; unable to safely manage at home; requires supervised medication administration"
    },
    {
      "disposition": "Discharge to supervised living",
      "criteria": "Chronic stable KS with persistent amnesia; unable to live independently; requires structured environment with medication management and meal supervision"
    },
    {
      "disposition": "Discharge home with caregiver",
      "criteria": "Medically stable; reliable caregiver available 24/7; caregiver educated on medication administration, safety precautions, and return triggers; outpatient follow-up arranged"
    },
    {
      "disposition": "Discharge home (independent)",
      "criteria": "Mild residual deficits only; demonstrated medication compliance capability; adequate nutrition independently; alcohol abstinence maintained; stable housing; outpatient follow-up arranged"
    },
    {
      "disposition": "Neurology follow-up",
      "criteria": "2-4 weeks post-discharge for cognitive reassessment; then q3-6 months for longitudinal monitoring"
    },
    {
      "disposition": "Addiction medicine follow-up",
      "criteria": "Within 1-2 weeks of discharge if alcohol use disorder present; ongoing relapse prevention program"
    },
    {
      "disposition": "Urgent readmission",
      "criteria": "Acute confusion or cognitive decline; suspected relapse with malnutrition; inability to maintain oral intake or medication compliance; new neurological symptoms"
    }
  ]
}